{
    "2018-12-04": [
        [
            {
                "time": "2018-12-09",
                "original_text": "AbbVie Falls 3%",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Falls",
                        "3%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-12-09",
                "original_text": "Roche Announces Positive Data on Venclexta/Venclyxto at ASH",
                "features": {
                    "keywords": [
                        "Roche",
                        "Announces",
                        "Positive",
                        "Data",
                        "Venclexta/Venclyxto",
                        "ASH"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-09",
                "original_text": "IMBRUVICAÂ® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "ibrutinib",
                        "Significantly",
                        "Improved",
                        "Survival",
                        "Phase 3",
                        "ASH 2018"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-09",
                "original_text": "JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial",
                "features": {
                    "keywords": [
                        "JNJ-AbbVie",
                        "cancer",
                        "drug",
                        "Imbruvica",
                        "succeeds",
                        "late-stage",
                        "trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-09",
                "original_text": "AbbVie Stock Could Become a New Happy Pill for Investors",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock",
                        "Happy",
                        "Pill",
                        "Investors"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}